Figure 6

HMGB1 induced cell migration through activation of the RAGE/AKT/GSK3β/β-catenin signaling pathway.

(a) BEAS-2B cells were treated with different doses of HMGB1 for 16 h and cell migration was detected by in vitro scratch assay. (b) Quantification of cell migration was performed by counting the cells in the wound in four fields per sample. Data are expressed as mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, as compared with the control group, in which cells were treated with PBS. (c) BEAS-2B cells were treated with different doses of HMGB1 for 16 h and cell proliferation was detected by BrdU-incorporation assay. Data are expressed as mean ± SD (n = 3). (d) Cells were pretreated with 10 μM of different inhibitors for 10 min and then treated with HMGB1 (300 ng/mL) for 16 h. Cell migration was detected by in vitro scratch assay. (e) Quantification of cell migration was performed by counting the cells in the rectangle in four fields per sample. Data are expressed as mean ± SD (n = 5). #p < 0.05, ##p < 0.01, as compared with the control group. ***p < 0.001, as compared with the HMGB1 group. (f) Stable clones expressing shRNAs targeting β-catenin (sh-β-catenin) and RAGE (sh-RAGE) were treated with HMGB1 (300 ng/mL) for 16 h. Cell migration was detected by in vitro scratch assay. (g) Quantification of cell migration was performed by counting the cells in the red rectangle in four fields per sample. Data are expressed as mean ± SD (n = 4) a^#p < 0.05, as compared with the control group. b^#p < 0.05, as compared with the vector group. a**p < 0.05, as compared to the PC group. b**p < 0.05, as compared to the vector treated with HMGB1.